FDA Advisory Panel Supports Staar Surgical Visian Toric Lens
This article was originally published in The Gray Sheet
FDA’s Ophthalmic Devices Panel voted in favor of Staar Surgical’s Visian toric implantable collamer lens to correct myopic astigmatism in adults ages 21 to 45. Earlier safety and missing data questions on the lenses were reviewed, but ultimately, the panel said the product’s proposed indication outweighed risk for use in specified patients.
You may also be interested in...
FDA is asking its Ophthalmic Devices Panel to consider the implications of missing data and issues with sizing methodology issues tied to Staar Surgical’s PMA submission for its Visian toric implantable collamer lens to correct myopic astigmatism in adults ages 21 to 45. The panel was scheduled for Feb. 14, but it has been postponed due to weather.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.